Pituitary Adenylate Cyclase Activating Polypeptide in Animal Models of Neurodegenerative Disorders - Implications for Huntington and Parkinson's Diseases

Publisher： Bentham Science Publishers

E-ISSN： 1875-628x|2|4|311-315

ISSN： 1570-1808

Source： Letters in Drug Design & Discovery, Vol.2, Iss.4, 2005-06, pp. : 311-315

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Hyperalgesia induced by pituitary adenylate cyclase-activating polypeptide in the mouse spinal cord

By Narita M.   Dun S.L.   Dun N.J.   Tseng L.F.  

European Journal of Pharmacology, Vol. 311, Iss. 2, 1996-09 ,pp. : 121-126

Elsevier

Access to resources Recommend Favorite

Pituitary Adenylate Cyclase Activating Polypeptide: A Potential Neuroprotective Peptide

By  

Current Pharmaceutical Design, Vol. 10, Iss. 23, 2004-09 ,pp. : 2861-2889

Bentham Science Publishers

Access to resources Recommend Favorite

Role of Pituitary Adenylate Cyclase-Activating Polypeptide in Nociception and Migraine

By  

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 14, Iss. 4, 2015-05 ,pp. : 540-553

Bentham Science Publishers

Access to resources Recommend Favorite

Protective Effects of Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) Against Apoptosis

By  

Current Pharmaceutical Design, Vol. 17, Iss. 3, 2011-01 ,pp. : 204-214

Bentham Science Publishers

Access to resources Recommend Favorite

The Secretin/Pituitary Adenylate Cyclase-Activating Polypeptide/ Vasoactive Intestinal Polypeptide Superfamily in the Central Nervous System

By  

Central Nervous System Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Central Nervous System Agents), Vol. 6, Iss. 1, 2006-03 ,pp. : 27-57

Bentham Science Publishers

Access to resources Recommend Favorite